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Abstract
BACKGROUND & AIMS: In the current era of emerging molecular targeted
drugs, it is necessary to identify before treatment the specific subclass to
which a tumour belongs. Gadoxetic acid is a liver-specific contrast agent that
is preferentially taken up by hepatocytes. Therefore, gadoxetic acid-enhanced
magnetic resonance imaging (EOB-MRI) should provide precise molecular
information about hepatocellular carcinomas (HCCs). The aim of this study was
to investigate the transporters of gadoxetic acid in HCC comprehensively and to
analyse the molecular regulatory mechanism of such transporters. METHODS :
Expression levels of transporters, transcriptional factors and Wnt target genes
in clinical samples were examined by quantitative real-time reverse transcription
polymerase chain reaction and immunohistochemistry. LiCl treatment of the HCC
cell line KYN-2 was conducted in vitro to assess the effects of Wnt signalling
activity. RESULTS: Comprehensive analyses of transporter mRNAs and protei...
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Background & Aims: In the current era of emerging molecular
targeted drugs, it is necessary to identify before treatment the
speciﬁc subclass to which a tumour belongs. Gadoxetic acid is a
liver-speciﬁc contrast agent that is preferentially taken up by
hepatocytes. Therefore, gadoxetic acid-enhanced magnetic reso-
nance imaging (EOB-MRI) should provide precise molecular
information about hepatocellular carcinomas (HCCs). The aim of
this study was to investigate the transporters of gadoxetic acid
in HCC comprehensively and to analyse the molecular regulatory
mechanism of such transporters.
Methods: Expression levels of transporters, transcriptional fac-
tors and Wnt target genes in clinical samples were examined
by quantitative real-time reverse transcription polymerase chain
reaction and immunohistochemistry. LiCl treatment of the HCC
cell line KYN-2 was conducted in vitro to assess the effects of
Wnt signalling activity.
Results: Comprehensive analyses of transporter mRNAs and pro-
tein expressions revealed that the organic anion transporting
polypeptide 1B3 (OATP1B3) had the strongest correlation with
tumour enhancement in hepatobiliary-phase images of EOB-
MRI. Association analysis with OATP1B3 expression revealed sig-
niﬁcant correlation with the expression of Wnt/b-catenin target
genes. Further, LiCl treatment induced OATP1B3 mRNA expres-
sion in KYN-2 cells, indicating a strong association between
OATP1B3 expression and Wnt/b-catenin signalling. The sensitiv-
ity and speciﬁcity to predict Wnt/b-catenin-activated HCC using
tumour enhancement in EOB-MRI were 78.9% and 81.7%,
respectively.
Conclusions: OATP1B3 was conﬁrmed as the most important
transporter mediating HCC enhancement in EOB-MRI. OATP1B3
expression showed a strong association with the expression of
Wnt/b-catenin target genes, therefore, OATP1B3-upregulated
HCC likely represents a speciﬁc subclass of Wnt/b-catenin-acti-
vated HCC.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent neo-
plasms and is the third most frequent cancer killer worldwide [1].
A 5-year survival rate of 60%–70% is achieved in well-selected
patients [2], but patients with advanced disease have a dismal
prognosis because HCC is highly resistant to conventional sys-
temic therapies. Although no curative systemic therapy is cur-
rently available, sorafenib, a multikinase inhibitor, has recently
demonstrated a survival beneﬁt for patients with advanced HCC
[3] and has shed light on the potential of molecular targeted ther-
apies for HCC. The molecular pathogenesis of HCC is complex, and
aberrations in several signalling cascades (e.g., p53, Wnt/b-cate-
nin and epidermal growth factor receptor) have been identiﬁed
[4]. Molecular classiﬁcations of HCC based on such signalling
disorders have been proposed using genome-wide data analyses
[5–12]; however, a more practical (ideally noninvasive) way to
stratify the molecular subclass of HCC is needed.
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Several imaging modalities are used for diagnosing HCC, such
as ultrasound, computed tomography and magnetic resonance
imaging (MRI). Gadoxetic acid (synonymous with gadolinium
ethoxybenzyl diethylenetriaminepentaacetic acid, Gd-EOB-DTPA)
is a liver-speciﬁc MRI contrast agent preferentially taken up by
hepatocytes. Whereas most HCCs show hypointensity compared
with background liver in hepatobiliary-phase images of gadoxetic
acid-enhanced MRI (EOB-MRI), some (6%–15%) HCCs show iso- or
hyperintensity [13]. Several researchers have investigated trans-
porters of gadoxetic acid in HCC [14–16] and identiﬁed the
organic anion transporting polypeptide 1B3 (OATP1B3) as one
such transporter. Consequently, EOB-MRI could offer molecular
information on HCC and could potentially discriminate a speciﬁc
molecular subclass of HCC.
The present study aimed to investigate comprehensively the
major transporters of gadoxetic acid in human HCC using mRNA
and protein expression levels, and then to analyze the molecular
regulatory mechanisms of such transporters.
Materials and methods
Patients
This study was conducted in accordance with the principles of the Declaration of
Helsinki [17] and was approved by our institutional review board. From April
2008 to March 2012, 101 nodules from 72 patients were enrolled in this study.
Patient characteristics are summarized in Supplementary Table 1. A total of 34
frozen samples of HCC from 32 patients were used in quantitative real-time
reverse transcription polymerase chain reaction (qRT-PCR) assessment. A detailed
description of the patients and the detailed method for qRT-PCR analysis are
given in the Supplementary materials and methods (M&M) section. The primers
are listed in Supplementary Table 2.
MRI interpretation
The MRI systems and the scanning protocol were the same as those used in our
previous study [18]. Image analysis was performed by one abdominal radiologist
(A.U. with 12 years of experience). The signal intensities (SIs) of the tumour and
surrounding background liver were measured by deﬁning regions of interest
(ROIs). Details are described in the Supplementary M&M section.
The relative enhancement of nodules compared with that of liver paren-
chyma was calculated following the method used by Tsuboyama et al. [16]: the
relative intensity ratio (RIR) = SInod/SIpar, where SInod is the nodule SI and SIpar
is the liver parenchyma SI, and the relative enhancement ratio (RER) = RIRHBP/
RIRpre, where RIRHBP is RIR in the hepatobiliary-phase images and RIRpre is the
precontrast RIR.
Pathologic diagnosis
Hematoxylin and eosin staining was carried out on tissue sections of all resected
specimens. HCCs were diagnosed by consensus of two liver pathologists (Y.M. and
M.S.), according to the classiﬁcation proposed by the Liver Cancer Study Group of
Japan [19]. We documented histologic features such as tumour grade, primary or
recurrent tumour, macroscopic growth patterns, architectural pattern, portal
venous invasion, and intrahepatic metastasis. Details are described in the
Supplementary M&M section. The stage of liver ﬁbrosis in the background liver
was deﬁned according to the METAVIR classiﬁcation [20]. Tumour cholestasis
was deﬁned as positive if bile pigment was observed inside the bile canaliculus,
pseudogland or cytoplasm in P5% of the tumour area [14,21].
Immunohistochemical analysis
Representative sections from the maximal diameter of tumours were used for
immunohistochemical analyses. The antibodies used in this study are listed in
Supplementary Table 3, and expression patterns in normal liver are given in
Supplementary Fig. 1. The detailed method for the immunohistochemistry is
described in the Supplementary M&M section.
Two authors (A.U. and Y.M.) semi-quantitatively evaluated in consensus the
intensity of the membranous expression of the transporters and the nuclear
expression of the hepatocyte nuclear factor 1a (HNF1a) in comparison with that
of background liver as follows: score 0, no expression; score 1, decreased expres-
sion compared to the background liver; score 2, equivalent expression; and score
3, increased expression. Cytoplasmic expression of glutamine synthetase (GS)
was classiﬁed as follows: no or weak expression, heterogeneous strong
expression, or diffuse strong expression [21]. For b-catenin assessment, nuclear
expression was deﬁned as positive when nuclear staining was observed in more
than 5% of the cells in the representative slide [22]. To avoid reading bias,
immunohistochemical analysis was performed at least 3 months after MRI
interpretation.
Cell culture and in vitro experiments
The human HCC cell line KYN-2 was used because of its low expression of Wnt
target genes [23]. Cells were placed in 6-well plates and incubated for 1 day prior
to treatment with 5 or 10 mM LiCl. Two days after LiCl addition, total RNA was
extracted. Cell culture and RNA extraction method were the same as previously
reported [23]. Wnt signalling activity was measured using the TCF-luciferase
reporter system (TOPﬂash/FOPﬂash, Upstate/Millipore, Billerica, MA, USA), and
the results are shown as the ratio of TOPﬂash to FOPﬂash (TOP/FOP).
Clinicopathological features in terms of tumour enhancement in EOB-MRI
We used GS diffuse strong expression in immunohistochemistry as a marker for
Wnt/b-catenin-activated HCC [21]. The optimum RER cut-off point for detecting
Wnt/b-catenin-activated HCC was determined using receiver operating charac-
teristics (ROC) curves. Sensitivity, speciﬁcity and accuracy were calculated using
this cut-off point.
Pathological features were compared between high- and low-RER nodules
classiﬁed using this cut-off point. Kaplan-Meier time-to-event curves were used
to estimate the overall survival and recurrence-free survival rates. Details are
described in the Supplementary M&M section.
Statistical analyses
Statistical analyses were performed using IBM SPSS statistics version 21.0 (IBM,
Armonk, NY, USA) and SAS version 9.2 (SAS Institute, Cary, NC, USA). A two-sided
p value of <0.05 was considered signiﬁcant in all analyses. Details are described in
the Supplementary M&M section.
Results
Hepatic transporter expressions and tumour enhancement in
hepatobiliary-phase images of EOB-MRI
Six ATP-binding cassette (ABC) and six solute carrier family (SLC)
transporters with relatively high mRNA expression levels (Sup-
plementary Fig. 2) were used for correlation analysis. Of these,
three ABC transporters (bile salt exporting pump [BSEP], multi-
drug resistance protein 2 [MRP2] and breast cancer resistance
protein [BCRP]) and four SLC transporters (Na+/taurocholate
co-transporting polypeptide [NTCP], OATP1B1, OATP1B3, and
OATP2B1) were correlated signiﬁcantly with RER (Table 1), and
the correlation coefﬁcient of OATP1B3 was the highest. On immu-
nohistochemical analysis, BSEP, OATP1B1/1B3 (recognizing both
OATP1B1 and OATP1B3) and OATP1B3 expression scores were
correlated signiﬁcantly with RER, but the other six were not
(Table 2). Representative examples of tumour enhancement in
hepatobiliary-phase images of EOB-MRI and immunohistochem-
ical staining of BSEP, OATP1B1/1B3 and OATP1B3 are given in
Fig. 1. Because all three transporters correlated positively with
RER and the correlation coefﬁcients of OATP1B1/1B3 and
OATP1B3 were almost the same, we considered that OATP1B3
was the most important transporter for tumour enhancement
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Table 1. Correlation analysis of tumour/liver mRNA expression ratio and RER.
ABC transporter MDR1 MDR3 BSEP MRP2 MRP3 BCRP
 0.322 0.203 0.53 0.482 0.075 0.723
 p value* 0.063 0.25 0.001 0.004 0.674 <0.001
SLC transporter NTCP OCT1 OAT2 OATP1B1 OATP1B3 OATP2B1
 0.477 -0.04 -0.012 0.544 0.761 0.375
 p value* 0.004 0.821 0.945 0.001 <0.001 0.029
⁄Pearson correlation analysis.
MDR, multidrug resistance; OCT1, organic cation transporter 1; OAT2, organic anion transporter 2.
Table 2. Correlation analysis of semi-quantitative immunohistochemical score and RER.
Transporter MDR* MDR1 BSEP MRP2 MRP3 BCRP OATP1B1/1B3† OATP1B3 OATP2B1
−0.008 −0.53 0.314 0.118 −0.02 −0.02 0.47 0.555 0.167
p value‡ 0.434 0.604 0.001 0.248 0.845 0.845 <0.001 <0.001 0.096
⁄MDR recognizes both MDR1 and MDR3.
OATP1B1/1B3 recognizes both OATP1B1 and OATP1B3.
Spearman’s correlation analysis.
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Fig. 1. Tumour enhancement patterns in hepatobiliary-phase images of EOB-MRI and immunohistochemistry. A hyperintense nodule in hepatobiliary-phase images
of EOB-MRI (A, arrow) showed strong expression of (C) BSEP, (D) OATP1B1/1B3, and (E) OATP1B3. A markedly hypointense nodule (F, arrow) showed very low expression of
(H) BSEP, (I) OATP1B1/1B3, and (J) OATP1B3. A slightly hypointense nodule (K, arrows) showed strong expression of (N) OATP1B1/1B3 but weak expression of (M) BSEP and
(O) OATP1B3. This strong expression of OATP1B1/1B3 is likely caused by OATP1B1 expression, but the tumour enhancement was negligible (K). B, G, and L are H&E staining
of correspondent HCC nodules. H&E, hematoxylin and eosin staining; N, non-tumoural liver; T, tumour. Scale bars = 0.5 mm.
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in hepatobiliary-phase images of EOB-MRI. Further investigations
of OATP1B3 were instigated.
OATP1B3 expression and pathological features
Immunohistochemical expression of OATP1B3 gradually
decreased during the multistep process of hepatocarcinogenesis
(p = 0.004, Fig. 2). All 14 recurrent tumours included in this study
and tumours with a conﬂuent multinodular growth pattern
showed no expression of OATP1B3. In terms of the architectural
patterns, expression of OATP1B3 was not observed in compact
or scirrhous patterns. Tumour cholestasis signiﬁcantly correlated
with OATP1B3 expression (p = 0.003). There was no signiﬁcant
correlation between OATP1B3 expression and portal venous inva-
sion, intrahepatic metastasis, or stage of liver ﬁbrosis in back-
ground liver (Table 3).
Association analysis with OATP1B3 expression
To analyse the possible regulatory mechanisms of OATP1B3, ﬁrst
we chose three genes reported to regulate OATP1B3 expression:
HNF1a [24], HNF3b [25], and the farnesoid X receptor (FXR)
[26]. Next, because OATP1B3 expression shows clear zonal differ-
entiation in normal liver (gradually increasing from periportal to
perivenular regions [Supplementary Fig. 1H]), we chose eight
genes reported to be expressed predominantly in the perivenular
region in murine liver: cytochrome P450 2E1 (CYP2E1), CYP7A1,
glutamine synthetase (GS), ornithine aminotransferase (OAT), cit-
rate transferase (CS), glucokinase (GCK), axis inhibition protein 2
(AXIN2), and the leucine-rich repeat-containing G-protein-
coupled receptor 5 (LGR5) [27].
For mRNA expression analysis, nodules were divided into an
OATP1B3 positive expression group (relative expression level
compared to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) P0.018; i.e., the average expression level of OATP1B3
in background liver  0.1, N = 14) and an OATP1B3 negative
expression group (relative expression level compared to GAPDH
<0.018, N = 20). Of the 11 genes analysed, expression levels of
CYP2E1, GS, OAT, AXIN2, and LGR5 (all reportedly associated with
Wnt/b-catenin signalling) were signiﬁcantly high in the OATP1B3
positive expression group. However, no signiﬁcant differences
were observed for HNF1a, HNF3b or FXR (Fig. 3). Further, the
immunohistochemical expression of GS and b-catenin nuclear
expression were signiﬁcantly correlated with that of OATP1B3,
but this was not the case for HNF1a (Supplementary Fig. 3).
Wnt/b-catenin signalling induces OATP1B3 mRNA expression
The above correlation analyses strongly suggest that OATP1B3
expression is closely associated with Wnt/b-catenin signalling.
We therefore conducted an in vitro study to investigate whether
activation of Wnt/b-catenin signalling can induce OATP1B3
expression in HCC cells. We treated KYN-2 cells with LiCl, an
activator of Wnt/b-catenin signalling. LiCl-treated KYN-2 cells
showed a signiﬁcant dose-dependent increase in the TOP/FOP
ratio compared to untreated cells (Fig. 4A), indicating that LiCl
treatment activates Wnt signalling in KYN-2 cells. Additionally,
qRT-PCR showed that mRNA expression of OATP1B3 was signiﬁ-
cantly upregulated in 10 mM LiCl in the same way that known
Wnt target genes AXIN2 and LGR5 were (Fig. 4B–D).
Clinicopathological features in terms of tumour enhancement in
EOB-MRI
The optimum RER cut-off point was determined as 0.90 using
ROC analysis (Supplementary Fig. 5). With this cut-off point,
the sensitivity, speciﬁcity and accuracy of prediction of Wnt/b-
catenin-activated HCC were 78.9%, 81.7%, and 81.2%, respectively
(Supplementary Table 4).
When nodules were divided into two groups (RER P0.9 and
RER <0.9), tumour enhancement was found to be signiﬁcantly
correlated with OATP1B3 expression score and GS diffuse strong
expression but not with tumour grade or tumour cholestasis
(Table 4). Neither was there a difference in overall survival nor
recurrence-free survival between patients with high-RER nodules
and low-RER nodules (Supplementary Fig. 6).
Discussion
Our comprehensive analysis indicated that, of the candidate
transporters studied, both mRNA and immunohistochemical
expression of OATP1B3 correlated most signiﬁcantly with tumour
enhancement in hepatobiliary-phase images of EOB-MRI, adding
convincing data to strengthen the ﬁndings of previous reports
[14–16]. The effect of OATP1B1 on tumour enhancement in hepa-
tobiliary-phase images of EOB-MRI appeared not to be strong
because the correlation coefﬁcient for OATP1B3 and RER were
slightly higher than for OATP1B1/1B3 and RER, and tumours
showing strong expression of OATP1B1/1B3 but negative expres-
sion of OATP1B3 exhibited weak enhancement in hepatobiliary-
phase images of EOB-MRI. Moreover, we considered the effect
of BSEP on tumour enhancement to be minor because it had a
positive correlation despite being an exporter. From our results,
it is reasonable to conclude that OATP1B3 is the most important
transporter affecting HCC enhancement in hepatobiliary-phase
images of EOB-MRI.
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Fig. 2. Immunohistochemical expression score of OATP1B3 and tumour
grade. OATP1B3 expression gradually decreased from high-grade dysplastic
nodules and early HCCs to well to poorly differentiated HCCs. Some well and
moderately differentiated HCCs exhibited strong expression of OATP1B3, but
overall, the OATP1B3 expression score and tumour differentiation grade corre-
lated signiﬁcantly (correlation coefﬁcient 0.287, p = 0.004, Spearman’s correla-
tion analysis). HGDN, high-grade dysplastic nodule; eHCC, early HCC; Well, well
differentiated HCC; Mod, moderately differentiated HCC; Poorly, poorly differen-
tiated HCC.
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In this study, OATP1B3 expression was found to decrease
gradually along with tumour dedifferentiation, although there
were some exceptions in which a few well to moderately differ-
entiated HCCs showed strong OATP1B3 expression. This ﬁnding
was consistent with those reported by Kitao et al. [28]. Along with
this result reﬂecting multistep hepatocarcinogenesis, all recur-
rent tumours exhibited no OATP1B3 expression in this study.
These results suggest that HCCs with aggressive phenotypes are
likely to have decreased OATP1B3 expression.
It has been reported that OATP1B3 is upregulated by HNF1a
[24] and FXR [26] but repressed by HNF3b [25]; however, the reg-
ulation of OATP1B3 is still unclear, especially in HCC. Thus, in
addition to these three genes, we further analysed correlations
between OATP1B3 and eight genes predominantly expressed in
the perivenular region. We found that ﬁve of these genes, CYP2E1,
GS, OAT, AXIN2, and LGR5, correlated signiﬁcantly with OATP1B3
expression on mRNA analysis, and all ﬁve had been previously
identiﬁed as Wnt/b-catenin related genes [27,29–31]. Further-
more, GS expression and b-catenin nuclear expression signiﬁ-
cantly correlated with the OATP1B3 expression score in
immunohistochemical analyses. From these results, we surmised
that there is a signiﬁcant association between OATP1B3 expres-
sion and Wnt/b-catenin signalling.
Tumour cholestasis also correlated signiﬁcantly with
OATP1B3 expression, which is similar to the results reported by
Sekine et al. [32]. Since tumour cholestasis was reported to have
a signiﬁcant correlation with HCC b-catenin mutations [21,32],
there might be strong associations among tumour cholestasis,
OATP1B3 expression and Wnt/b-catenin signalling. However,
our ﬁndings suggest that there might be a more solid association
between OATP1B3 expression and Wnt/b-catenin signalling,
since there were no signiﬁcant correlations between OATP1B3
expression and genes reported to be associated with cholestasis,
such as HNF1a and FXR [24,26], in our mRNA analyses. However,
further investigation will be needed to clarify these relationships.
b-Catenin is the major downstream mediator of the canonical
Wnt signalling pathway. In the Wnt activated state, glycogen
synthase kinase-3b (GSK3b) and axin, which form the adenoma-
tous polyposis coli protein complex, are inhibited and degraded,
and consequently, b-catenin is free to translocate to the nucleus,
where it can mediate transcription of various Wnt target genes.
Wnt/b-catenin signalling is known to play many critical roles in
both normal and diseased liver [33]. One important role is regu-
lating liver zonation. GS is known to be predominantly expressed
in perivenular hepatocytes and is one of the Wnt target genes in
the liver [30]. Wnt/b-catenin signalling is also implicated in the
development of HCC. b-Catenin mutations can result in activation
of the Wnt signalling pathway and are reportedly found in nearly
one-quarter of HCC cases [34,35]. We used LiCl, a GSK3b inhibi-
tor, as a Wnt signalling activator in cells of the HCC cell line
KYN-2 and found that OATP1B3 mRNA expression was induced
by LiCl treatment. To our knowledge, this is the ﬁrst report
addressing OATP1B3 expression induced by Wnt/b-catenin
signalling in HCC cells using in vitro experiments.
Several molecular subclassiﬁcations of HCCs have been
proposed as a result of genome-wide data analyses [5–11].
Table 3. Pathological characteristics of 101 HCC nodules on the basis of OATP1B3 immunohistochemical expression.
Number of nodules OATP1B3 expression score p value*
0 1 2 3
Macroscopic growth pattern
Recurrent tumour 14 14 0 0 0 <0.001
SNIM 16 4 6 6 0
SN 29 16 6 3 4
SNEG 32 22 4 5 1
CM 7 7 0 0 0
Others 3 2 1 0 0
Architectural pattern
Trabecular 70 40 15 12 3 0.027
Pseudoglandular 16 10 2 2 2
Compact 6 6 0 0 0
Scirrhous 9 9 0 0 0
Portal venous invasion
+ 42 31 5 5 1 0.102
− 59 34 12 9 4
Intrahepatic metastasis
+ 9 7 1 1 0 0.367 
− 92 58 16 13 5
Tumour cholestasis
+ 27 11 8 4 4 0.003
− 74 54 9 10 1
0-2 50 34 6 7 3 0.630
3-4 51 31 11 7 2
⁄Cochran–Mantel–Haenszel mean score test.
SNIM, small nodular with indistinct margin; SN, simple nodular; SNEG, simple nodular with extranodular growth; CM, conﬂuent multinodular.
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Activation of the Wnt/b-catenin signalling pathway has been
identiﬁed as a signiﬁcant molecular signature in HCC and has
been used to deﬁne a speciﬁc HCC subclass. Boyault’s G5 and
G6 subclasses [7] and Chiang’s CTNNB1 subclass [8] are related
to Wnt/b-catenin signalling. Our results show that OATP1B3
expression strongly correlated with genes such as GS and LGR5,
indicating that OATP1B3-upregulated HCC might represent a spe-
ciﬁc subclass of Wnt/b-catenin-activated HCC. These data were
consistent with both the ﬁndings of Zucman-Rossi et al. that GS
and LGR5 were signiﬁcantly overexpressed in b-catenin-mutated
HCCs [36] and also with the ﬁnding that liver zonation occurs
through a b-catenin-dependent mechanism [37].
In contrast to the ﬁndings by Kitao et al. [13], there were no
differences in overall survival or recurrence-free survival
between patients with high-RER nodules and with low-RER nod-
ules. However, invasive tumour characteristics such as portal
venous invasion and intrahepatic metastasis were seen less fre-
quently in HCCs expressing OATP1B3, though the correlation
was not statistically signiﬁcant. Moreover, we have reported pre-
viously that LGR5-overexpressing HCC cells showed a more nod-
ular and less metastatic phenotype [23], and Vasuri et al. reported
that OATP1B1/1B3-positive HCCs did not have the aggressive fea-
tures which K7/19-expressing HCCs had [38]. Thus, we consider
that the aggressiveness of OATP1B3-upregulated HCC is still
undeﬁned and further studies will be needed to determine the
prognosis of this HCC subclass. Nevertheless, deﬁning an
OATP1B3-upregulated HCC subclass would be useful in the cur-
rent era of rapid development in molecular targeted therapies,
particularly with the advantage that tumours could be classiﬁed
non-invasively using EOB-MRI.
OATP1B3 HNF1α HNF3β FXR
CYP2E1 CYP7A1 GS OAT
CS GCK AXIN2 LGR5
p <0.001 p <0.001
p <0.001 p <0.001
p <0.001
p = 0.457 p = 0.328 p = 0.118
p = 0.663
p = 0.221 p = 0.716
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Fig. 3. mRNA expression of various genes in tumour nodules analysed with respect to OATP1B3 expression. The mRNA expressions of (B) HNF1a, (C) HNF3b, (D) FXR, (E)
CYP2E1, (F) CYP7A1, (G) GS, (H) OAT, (I) CS, (J) GCK, (K) AXIN2, and (L) LGR5 were compared with positive and negative mRNA expression of OATP1B3. (A) OATP1B3 mRNA
expression relative to GAPDH P0.018 was deﬁned as the positive expression group (+, n = 14) and <0.018 as the negative expression group (, n = 20). CYP2E1, GS, OAT,
AXIN2, and LGR5 expressions were signiﬁcantly higher in the OATP1B3 positive expression group (Mann–Whitney U test).
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Fig. 4. In vitro LiCl treatment of KYN-2 cells. (A) The TOP/FOP signal ratio
increased dose-dependently on 5 and 10 mM LiCl treatment. This result suggests
that activation of Wnt/b-catenin signalling occurs in LiCl-treated KYN-2 cells.
(B) OATP1B3 mRNA expression was induced on treatment with 10 mM LiCl in the
same way as (C) the known Wnt target genes AXIN2 and (D) LGR5. For each
concentration of LiCl, mean value and standard deviation are represented.
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For the detection of Wnt/b-catenin-activated HCC using EOB-
MRI, both the sensitivity and speciﬁcity were around 80% with an
RER cut-off point of 0.9. These results might be acceptable for
noninvasive diagnosis, but they could be improved, along with
the reproducibility of single measurements, as a result of ongoing
technological developments (e.g., direct measurement and/or
computer-aided measurement of tumour enhancement or a more
speciﬁc contrast agent for OATP1B3). We preferred to use an RER
cut-off point than to rely on visual assessment for detecting mild
enhancement of the nodules. Therefore, the number of enhanced
nodules detected in this study was relatively higher than that
previously reported [13].
In conclusion, we found that OATP1B3 is the most important
transporter mediating HCC enhancement in hepatobiliary-phase
images of EOB-MRI, and OATP1B3 expression showed strong
association with Wnt/b-catenin signalling. Therefore OATP1B3-
upregulated HCC is a good candidate for a speciﬁc subclass of
Wnt/b-catenin-activated HCC.
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